Cargando…

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review

Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabetes mellitus are common side effects of anti-tumor drug use that present mainly as hyperglycemia. Here, we present two case reports of diabetes mellitus caused by the use of tremelimumab and apalutami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yue, Zhong, Mingyao, Gan, Lulu, Xiang, Cheng, Li, Ling, Yan, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509015/ https://www.ncbi.nlm.nih.gov/pubmed/37732122 http://dx.doi.org/10.3389/fendo.2023.1236946

Ejemplares similares

Transient low T3 syndrome in patients with COVID-19: a new window for prediction of disease severity
por: Zhong, Mingyao, et al.
Publicado: (2023)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
por: Hong, A Ram, et al.
Publicado: (2020)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
por: Starzyk, Tory, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects
por: Iwamoto, Yuichiro, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
por: Burnett, Deborah L., et al.
Publicado: (2023)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
por: Gully, Christopher P, et al.
Publicado: (2010)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
por: Goncalves, Marcus D., et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
por: Hilder, Robin, et al.
Publicado: (2023)

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021
por: Zhang, Hongyi, et al.
Publicado: (2023)

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
por: Brana, Irene, et al.
Publicado: (2012)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
por: Zhao, Wennan, et al.
Publicado: (2017)

Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
por: Šála, Michal, et al.
Publicado: (2016)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
por: Telkoparan-Akillilar, Pelin, et al.
Publicado: (2019)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021)

Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
por: Lee, Hanna J., et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Early Detection of Immune-Mediated Hypophysitis With Use of Checkpoint Inhibitor Immunotherapy
por: Yossef, Kristena, et al.
Publicado: (2022)

Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds
por: Sauvey, Conall, et al.
Publicado: (2021)

Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
por: Fang, Xiaosheng, et al.
Publicado: (2013)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Development of selective inhibitors of phosphatidylinositol 3-kinase C2α
por: Lo, Wen-Ting, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System
por: Lu, Difei, et al.
Publicado: (2022)

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis
por: Liang, Xueyan, et al.
Publicado: (2023)

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
por: Vella, Veronica, et al.
Publicado: (2017)

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
por: Cerquetti, Lidia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_soels2tbcs79dloke0cgnlmava